Macrogenics (MGNX) Operating Expenses (2012 - 2026)

Macrogenics (MGNX) has 15 years of Operating Expenses data on file, last reported at $54.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $54.2 million, down 2.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $220.7 million (down 12.92% YoY), and the FY2025 annual result was $222.3 million, down 14.66% from the prior year.
• Operating Expenses grew to $54.2 million in Q1 2026 per MGNX's latest filing, from $53.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $77.7 million in Q1 2022 and troughed at $45.9 million in Q3 2023.
• A 5-year average of $61.0 million and a median of $60.1 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 31.17% in 2023, then increased 23.13% in 2024.
• A 5-year view of Operating Expenses shows it stood at $61.1 million in 2022, then fell by 1.71% to $60.1 million in 2023, then rose by 20.17% to $72.2 million in 2024, then dropped by 26.13% to $53.3 million in 2025, then gained by 1.67% to $54.2 million in 2026.
• Business Quant data shows MGNX's Operating Expenses at $54.2 million in Q1 2026, $53.3 million in Q4 2025, and $54.2 million in Q3 2025.